| Oct 11 |
Exploring Three High Growth Tech Stocks in the United States
|
| Oct 10 |
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
|
| Oct 9 |
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
|
| Oct 3 |
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
|
| Oct 2 |
The Play On Neurocrine Biosciences
|
| Sep 30 |
Neurocrine touts long-term effectiveness of Ingrezza for Huntington's disease chorea
|
| Sep 30 |
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
|
| Sep 19 |
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
|
| Sep 14 |
Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock
|
| Sep 13 |
Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint
|
